BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy Asset
Why now
Thesis: Pharma RLT licensing signals oncology pipeline appetite
Catalyst to watch: Deal terms or further RLT deals
Main risk: BoomRay private, terms undisclosed
Why it matters
A licensing deal for a radioligand therapy asset signals continued pharma appetite for oncology RLT pipelines, though BoomRay is private and terms are undisclosed.
Details
SUZHOU, China, Sept. 22, 2026 /PRNewswire/ -- Boomray Pharmaceuticals Co., Ltd. ("BoomRay"), a clinical-stage biotechnology company pioneering innovative radioligand therapies (RLTs) for precision oncology diagnostics and therapeutics, today announced that it has entered into an exclusive...
Sources
- prnewswire · 2026-09-22 04:00 UTC